|Bid||38.02 x 800|
|Ask||44.97 x 800|
|Day's range||41.33 - 42.38|
|52-week range||28.03 - 48.50|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.
Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.
Joining me on the call today are our President and Chief Executive Officer, Jon Serbousek; and Chief Financial Officer, Doug Rice. During this call, we will be making forward-looking statements that involve risks and uncertainties.